Accustem Sciences (Accustem Sciences) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Accustem Sciences's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Accustem Sciences's average Total Assets over the quarter that ended in Mar. 2024 was $0.09 Mil. Therefore, Accustem Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

Accustem Sciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Accustem Sciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Gross-Profit-to-Asset % Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Gross-Profit-to-Asset %

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Accustem Sciences's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Accustem Sciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Gross-Profit-to-Asset % falls into.

Accustem Sciences Gross-Profit-to-Asset % Calculation

Accustem Sciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (0.94	+	0.134)	/ 2 )
	=	0	/	0.537
	=	0.00 %

Accustem Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (0.134	+	0.051)	/ 2 )
	=	0	/	0.0925
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Accustem Sciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Accustem Sciences (Accustem Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001

Website

http://www.accustem.com

Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.